Top 500 Medicines Pharma

8/9/2019 Top 500 Medicines Pharma

1/69

PharmaLive and Med Ad Newseditors have ranked thebest-selling prescription medicines by 2007 worldwidesales in this annual special report.

As part of this detailed report, the editors researchedand compiled the 2007, 2006, and 2005 worldwidesales information of the prescription medicines thatpharmaceutical, biotechnology, and specialty companies

manufacture and sell.

SPECIAL REPORT JULY 2008

TOP 500

PRESCRIPTION

MEDICINES

WHATYOUWILLFINDINTHISSPECIALREPORT


2/69

2

What you will find in this special report(continued)

The information in this report is supplied by the companies. This document provides information on 500product sales entries representing about 100 companies. Some products that generate enough salesto make the top 500 list are not represented in these charts due to the unavailability of published salesdata. For instance, certain companies publish sales information for only billion-dollar brands, or for onlytheir top 10 or 20 drugs, etc. Certain companies do not publish any product sales data.

The data are sorted and presented in three formats: by the highest product 2007 global sales, by thecompanies that report sales for these products, and by the primary disease/medical use that eachproduct treats.

Some medicines are represented more than once in the Company chart because their sales are reportedseparately by more than one company due to joint promotion, joint marketing, or other types of alliancesand deals. In the Sales and Primary Disease/Medical Use charts, the products with more than onecompany are represented as one combined sales entry.

The charts provide the following information: 2007 sales rank for each medicine 2007, 2006 and 2005 worldwide sales for each medicine Companies that report sales for each medicine At least one primary disease/medical use that each medicine treats First approval date (or launch date if the original approval date is not applicable) of each medicine,and in some instances the region of occurrence is provided.

The top 500 prescription medicine entries of 2007 generated total sales of about $397 billion, comparedwith $369 billion for the same 500 drug entries during 2006 and $333 billion for 2005. The top-sellingprescription medicine remains Lipitor (lipitor.com). Launched during the first quarter of 1997, the HMG-CoA reductase inhibitor garnered 2007 sales of $12.68 billion for marketer Pfizer Inc. (pfizer.com). TokyosAstellas Pharma Inc. (astellas.com) reported Lipitor sales of 97.7 billion ($977 million) for the fiscalyear ended March 31, 2008. These combined sales of $13.65 billion compare with $13.83 billion for the

previous annual term. The No. 2 best-selling medicine worldwide in annual sales last year was Plavix/Iscover. Sales reached $8.08 billion in 2007, compared to $6.31 billion for 2006 when the product rankedthird overall. An antiplatelet agent indicated for a variety of atherothrombotic conditions, Plavix (plavix.com) was launched in 1998 in the United States. The medicine is marketed in more than 80 countries, insome regions under the trade name Iscover. Bristol-Myers Squibb Co. (bms.com) recorded Plavix salesof $4.76 billion for 2007. Sanofi-Aventis (sanofi-aventis.com) reported Plavix/Iscover sales of E2.42billion($3.32 billion) for last year.

Coming in at the No. 3 medicine sales rank was Advair/Seretide, at $6.99 billion for 2007.GlaxoSmithKline (gsk.com) reported Advair/Seretide sales of $6.63 billion in 2006 when the drug was theworlds No. 2 prescription seller. For treating asthma and chronic obstructive pulmonary disease, Advair(advair.com) was approved in the United States in 2000 and Seretide was cleared for EU marketing in1998. Climbing from the No. 11 sales rank (for 2005) to No. 7 (in 2006) to No. 4 last year was Enbrel.The tumor necrosis factor inhibitor generated $5.46 billion in 2007, up from $4.49 billion during theprevious term. Initially cleared for marketing in 1998, Enbrel (enbrel.com) is approved for a variety ofarthritic conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. For 2007,Enbrel sales were reported at $3.23 billion for Amgen (amgen.com) and $2.05 billion for Wyeth (wyeth.com). For the fiscal year ended March 31, 2008, Takeda (takeda.com) reported Enbrel sales of 18.8billion ($188 million). Ranking No. 14 in 2005 and No. 8 in 2006, Remicade was the No. 5 global sellerlast year at about $5.26 billion compared with $4.46 billion in the previous annum. Last years Remicadesales were reported to be $3.33 billion for Johnson & Johnson (jnj.com), $1.65 billion for Schering-Plough Corp. (sgp.com), and 28.6 billion ($286 million) for Mitsubishi Tanabe Pharma Corp. (mt-pharmaco.jp). Initially FDA approved in 1998, Remicade is a treatment for inflammatory diseases.


3/69

3

TABLE OF CONTENTS

TOP 500 PRESCRIPTION MEDICINES BY SALESpages 5-27

TOP 500 PRESCRIPTION MEDICINES BY COMPANYpages 29-47

TOP 500 PRESCRIPTION MEDICINES BY PRIMARYDISEASE/MEDICAL USEpages 49-69


4/69

TOP 500PRESCRIPTION

MEDICINES

BY SALES


5/69

5

TOP 500 PRESCRIPTION MEDICINES BY SALES

Rank2007 Medicine

2007 sales($ in millions)


2005 sales($ in millions) 2007 company

Primary disease/medical use

First approval date(or launch date)

1 Lipitor 13,652

Pfizer 12,675

Astellas 977

13,833

Pfizer 12,886

Astellas 947

13,102

Pfizer 12,187

Astellas 915

Pfizer andAstellas Pharma

Cholesterol Dec. 17, 1996

2 Plavix/Iscover 8,079

BMS 4,755

Sanofi-Aventis3,324

6,313

BMS 3,257

Sanofi-Aventis3,056

6,601

BMS 3,823

Sanofi-Aventis2,778

Bristol-Myers Squibband Sanofi-Aventis

Atherothrombosis Nov. 17, 1997/1998

3 Advair/Seretide 6,998 6,626 6,006 GlaxoSmithKline Asthma Aug. 24, 2000/Sept. 7, 1998

4 Enbrel 5,463

Amgen 3,230

Wyeth 2,045

Takeda 188

4,493

Amgen 2,879

Wyeth 1,500

Takeda 114

3,707

Amgen 2,573

Wyeth 1,084

Takeda 50

Amgen,Wyeth,TakedaPharmaceutical

Rheumatoid arthritis Nov. 2, 1998

5 Remicade 5,261

J&J 3,327

Schering-Plough

1,648

MitsubishiTanabe 286

4,458

J&J 3,013

Schering-Plough

1,240

Mitsubishi 205

3,605

J&J 2,535

Schering-Plough

942

Mitsubishi 128

Johnson & Johnson,Schering-Plough,Mitsubishi TanabePharma

Rheumatoid arthritis Aug. 24, 1998

6 Nexium 5,216 5,182 4,633 AstraZeneca Gastrointestinal disorders March 2000 (Sweden)

7 Rituxan/MabThera

Notes: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent companyRoche

Biogen Idec recordsU.S. joint-promotionprofitt

5,214

Roche 4,597(includesGenentech2,285 andChugai 159)

Biogen Idec 617

Zenyaku KogyoNA

4,589


Biogen Idec 556

Zenyaku KogyoNA

3,976


Biogen Idec 514

Zenyaku KogyoNA

Roche,Genentech,Biogen Idec,ChugaiPharmaceutical,Zenyaku Kogyo

Non-Hodgkins lymphoma Nov. 26, 1997/June 2, 1998

8 Diovan and DiovanHCT/CoDiovan

5,012 4,223 3,676 Novartis Hypertension Dec. 23, 1996 andMarch 6, 1998/Oct. 6, 1997

9 Zyprexa 4,761 4,364 4,202 Eli Lilly Schizophrenia Sept. 27, 1996

10 Risperdal, RisperdalConsta, Invega

4,697 4,183 3,552 Johnson & Johnson Schizophrenia Dec. 29, 1993,Oct. 29, 2003,Dec. 19, 2006

11 Actos 4,333

Takeda 3,962

Eli Lilly 371

3,812

Takeda 3,363

Eli Lilly 449

2,931

Takeda 2,438

Eli Lilly 493

TakedaPharmaceutical andEli Lilly

Type 2 diabetes July 15, 1999

12 Singulair 4,266 3,579 2,976 Merck & Co. Asthma Feb. 20, 1998

13 Protonix/Pantozol/Pantoloc

(pantoprazole)

Notes: Nycomedacquired AltanaPharma andPantoprazoleDec. 29, 2006.

Solvay lost Pantolocmarketing rightsin Canada during2006.

4,221

Nycomed 2,310(Pantoprazole,includingPantozol)

Wyeth 1,911(Protonix)

Solvay 0(Pantoloc)

4,017

Altana 2,126(Pantoprazole,includingPantozol)


Solvay 96(Pantoloc)

3,779

Altana 1,866(Pantoprazole,includingPantozol)


Solvay 228(Pantoloc)

Nycomed andWyeth

Gastrointestinal disorders Feb. 2, 2000/1994/1997

14 Seroquel 4,219

AstraZeneca4,027

Astellas 192

3,584

AstraZeneca3,416

Astellas 168

2,913

AstraZeneca2,761

Astellas 152

AstraZeneca andAstellas Pharma

Schizophrenia Sept. 26, 1997


6/69


6

Rank2007 Medicine






15 Herceptin

Note: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent company

Roche

4,044


3,273


1,788

Roche 1,788(includesGenentech 747and Chugai 96)

Roche,Genentech,ChugaiPharmaceutical

Breast cancer Sept. 25, 1998

16 Prevacid/Takepron(lansoprazole)

3,962

Tap 2,275(Prevacid)

Takeda 1,487(Lansoprazole,including 648 forTakepron)

Abbott 200(Lansoprazole)

4,280

Tap 2,600(Prevacid)



4,254

Tap 2,501(Prevacid)



Tap PharmaceuticalProducts,TakedaPharmaceutical,Abbott Laboratories

Gastrointestinal disorders May 10,1995/1991

17 Effexor line 3,794 3,722 3,459 Wyeth Depression Dec. 28, 1993

18 Aranesp 3,614 4,121 3,273 Amgen Anemia June 11, 2001

19 Lovenox/Clexane 3,581 3,339 2,938 Sanofi-Aventis Deep-vein thrombosis March 29, 1993/September 1997

20 Atacand/Blopress(candesartan)

3,518

Takeda 2,231(Blopress/candesartan)

AstraZeneca1,287 (Atacand)

3,172


AstraZeneca1,110 (Atacand)

2,883


AstraZeneca 974(Atacand)

TakedaPharmaceutical andAstraZeneca

Hypertension June 4, 1998/Oct. 6, 1997

21 Avastin

Note: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent companyRoche.

3,422


2,469

Roche 2,469(includesGenentech1,746; Chugai0 = June 2007Japan launch

1,388

Roche 1,388(includesGenentech1,133)

Roche,Genentech,ChugaiPharmaceutical

Colorectal cancer Feb. 26, 2004(U.S. approval)

22 Cozaar and Hyzaar 3,350 3,163 3,037 Merck & Co. Hypertension April 14, 1995, andApril 28, 1995

23 Copaxone 3,327

Teva 1,713

Sanofi-Aventis1,614

2,880

Teva 1,414

Sanofi-Aventis1,466

2,413

Teva 1,176

Sanofi-Aventis1,237

Teva PharmaceuticalIndustries andSanofi-Aventis

Multiple sclerosis Dec. 20, 1996

24 Aricept 3,311

Eisai 2,910

Pfizer 401

2,887

Eisai 2,529

Pfizer 358

2,311

Eisai 1,965

Pfizer 346

Eisai and Pfizer Alzheimers disease Nov. 25, 1996

25 AcipHex/Pariet 3,116

Eisai 1,759

J&J 1,357

2,982

Eisai 1,743

J&J 1,239

2,714

Eisai 1,545

J&J 1,169

Eisai andJohnson & Johnson

Gastrointestinal disorders Aug. 19, 1999/1997

26 Humira 3,064 2,044 1,400 Abbott Laboratories Rheumatoid arthritis Dec. 31, 2002

27 Gleevec/Glivec 3,050 2,554 2,170 Novartis Leukemia May 10, 2001/June 26, 2001

28 Fosamax 3,049 3,134 3,191 Merck & Co. Osteoporosis Sept. 29, 1995

29 Lexapro/Cipralex 3,044

Forest 2,292(Lexapro)

Lundbeck 752(Cipralex)

2,751



2,355



Forest LaboratoriesandH. Lundbeck

Major depressive disorder Aug. 14, 2002/2002

30 Norvasc 3,001 4,866 4,706 Pfizer Hypertension July 31, 1992

31 Neulasta 3,000 2,710 2,288 Amgen Neutropenia Jan. 31, 2002


7/69

7


Rank2007 Medicine






32 Crestor 2,900

AstraZeneca2,796

Shionogi 104

2,053

AstraZeneca2,028

Shionogi 25

1,269

AstraZeneca1,268

Shionogi 1

AstraZeneca andShionogi

Cholesterol Nov. 7, 2002

33 Procrit/Eprex 2,885 3,180 3,324 Johnson & Johnson Anemia Dec. 31, 1990/

May 4, 199534 Levaquin/Cravit

(levofloxacin) andFloxin, Floxin Otic

2,862J&J 1,646

(Levaquin,Floxin, FloxinOtic)

Daiichi Sankyo1,087 (Cravit/levofloxacin)

Santen 129(Cravit)

2,703

J&J 1,530(Levaquin,Floxin, FloxinOtic)


Santen 132(Cravit)

2,639

J&J 1,492(Levaquin,Floxin, FloxinOtic)


Santen 132(Cravit)

Johnson & Johnson,

Daiichi Sankyo,

SantenPharmaceutical

Bacter ial infections Levaquin: Dec. 20, 1996

Cravit: 1993

Floxin: Dec. 28, 1990

Floxin Otic: Dec. 16, 1997

35 Lantus 2,785 2,284 1,665 Sanofi-Aventis Type 2 diabetes andtype 1 diabetes

April 20, 2000

36 Vytorin 2,779 1,955 1,028 Merck/Schering-Plough

Pharmaceuticals

Cholesterol July 23, 2004

37 Avapro/Aprovel andAvalide/CoAprovel

2,685

Sanofi-Aventis1,481 (Aproveland CoAprovel)

Bristol-MyersSquibb 1,204(Avapro/Aproveland Avalide/CoAprovel)

2,489


Bristol-MyersSquibb 1,097(Avapro/Aproveland Avalide/CoAprovel)

2,205


Bristol-MyersSquibb 982(Avapro/Aproveland Avalide/CoAprovel)

Sanofi-AventisandBristol-Myers Squibb

Hypertension Avapro: Sept. 30, 1997

Aprovel: Aug. 27, 1997

Avalide: Sept. 30, 1997

CoAprovel:Oct. 15, 1998

38 Taxotere 2,569 2,402 2,206 Sanofi-Aventis Cancer Oct. 27, 1995

39 Abilify

Note: 2007-2005total figures are

estimates; 2007-2005 U.S. sales areactual numbers.

2,490(estimate)

Bristol-Myers

Squibb 1,660

Otsuka 830(estimate)

*2007 U.S. salesfor BMS andOtsuka total2,160.

1,923(estimate)

Bristol-Myers

Squibb 1,282



1,368(estimate)

Bristol-Myers

Squibb 912



Bristol-Myers SquibbandOtsukaPharmaceutical

Schizophrenia Nov. 15, 2002

40 Epogen 2,489 2,511 2,455 Amgen Anemia June 1, 1989

41 Spiriva 2,457 1,893 1,304 Boehringer Ingelheim Chronic obstructivepulmonary disease

April 2002

42 Topamax 2,453 2,027 1,680 Johnson & Johnson Seizures Dec. 24, 1996

43 Prevnar 2,439 1,961 1,508 Wyeth Pneumococcal disease Feb. 17, 2000

44 Zetia 2,407 1,929 1,397 Merck/Schering-Plough

Pharmaceuticals

Cholesterol Oct. 25, 2002

45 Celebrex/Celecox 2,327

Pfizer 2,290

Astellas 37(June 2007Japan launch)

2,039(Pfizer)

1,730(Pfizer)

Pfizer andAstellas Pharma

Osteoarthritis andrheumatoid arthritis

Celebrex: February1999 (U.S. launch)

Celecox: June 11, 2007(Japan launch)


8/69


8

Rank2007 Medicine






46 Zyrtec/Cirrus andZyrtec-D

Note:GlaxoSmithKlinejointly marketsZyrtec in Japan.

2,317+

Pfizer 1,541(Zyrtec andZyrtec-D)

UCB 668(Zyrtec/Cirrus

and Zyrtec-D)

Daiichi Sankyo108 (Zyrtec)

GlaxoSmithKlineNA(Zyrtec)

2,458+



and Zyrtec-D)



2,259+



and Zyrtec-D)



Pfizer,UCB,Daiichi Sankyo

Allergic rhinitis Dec. 8, 1995/NA andAug. 10, 2001

47 Lamictal 2,194 1,992 1,698 GlaxoSmithKline Seizures Dec. 27, 1994

48 Micardis 2,166

Boehringer 1,540

Astellas 626

1,829

Boehringer 1,326

Astellas 503

1,366Boehringer 993

Astellas 373

Boehringer IngelheimandAstellas Pharma

Hypertension Nov. 10, 1998

49 Benicar/Olmetecand Benicar HCT(olmesartan)

Note: Forestrecords U.S. jointpromotion profit.

2,104

Daiichi 1,892

(Benicar/Olmetec andBenicar HCT(olmesartan))

Forest 212(Benicar andBenicar HCT)

1,622

Daiichi 1,447



1,038

Daiichi 924



Daiichi SankyoandForest Laboratories

Hypertension April 25, 2002/2002 andJune 5, 2003

50 Cymbalta 2,103 1,316 680 Eli Lilly Depressive disorder Aug. 3, 2004

51 Eloxatin/Eloxatine 2,085 2,321 2,144 Sanofi-Aventis Colorectal cancer Aug. 9, 2002/September 1996

52 Prograf 2,030 1,754 1,459 Astellas Pharma Transplant rejection April 2, 1993

53 Lupron/Leuplin(leuprolide)

1,885Takeda 1,240(Leuprorelin,including 664 for

Leuplin)

Tap 645 (Lupron)

Abbott NA(Leuprolide)

2,167

Takeda 1,275(Leuprorelin,including 643 for

Leuplin)

Tap 662 (Lupron)

Abbott 230(Leuprolide)

2,142

Takeda 1,224(Leuprorelin,including 632 for

Leuplin)

Tap 699 (Lupron)

Abbott 219(Leuprolide)

TakedaPharmaceutical andTap PharmaceuticalProducts

Prostate cancer Jan. 26, 1989/July 5, 2002

54 Avonex 1,868 1,707 1,543 Biogen Idec Multiple sclerosis May 17, 1996

54 Valtrex 1,868 1,690 1,390 GlaxoSmithKline Herpes June 23, 1995

56 Lyrica 1,829 1,156 291 Pfizer Neuropathic pain July 6, 2004

57 TriCor/Lipanthyl 1,812

Abbott 1,218(TriCor)

Solvay 594(TriCor/Lipanthyl)

1,614Abbott 1,048(TriCor)


1,181

Abbott 927(TriCor)


Abbott Laboratoriesand Solvay

Cholesterol Feb. 9, 1998/June 1999

58 Viagra 1,764 1,657 1,645 Pfizer Erect ile dysfunction March 27, 1998

59 Avandia 1,754 2,798 2,308 GlaxoSmithKline Type 2 diabetes May 25, 1999

60 Actonel

Notes: 2007 total isactual worldwidefigure; P&G figuresare estimates.

Eisai marketsActonel in Japan.

1,750(actual)

P&G 1,229(estimate)

Sanofi-Aventis439

Eisai 82

1,663(estimate)

P&G 1,106(estimate)

Sanofi-Aventis481

Eisai 75

1,582(estimate)

P&G 1,043(estimate)

Sanofi-Aventis499

Eisai 40

Procter & Gamble,Sanofi-Aventis,Eisai

Osteoporosis March 27, 1998


9/69

9


Rank2007 Medicine






61 NeoRecormon/Epogin

Note: Chugaireports Japansales that are alsorecorded by parentcompany Roche.

1,745Roche 1,745(includesChugai 468)



Roche andChugaiPharmaceutical

Anemia July 16, 1997/April 1990

62 Tamiflu


1,738

Roche 1,738(includesChugai 331)

2,189


1,298



Influenza Oct. 27, 1999

63 Arimidex 1,730 1,508 1,181 AstraZeneca Breast cancer Dec. 27, 1995

64 Ambien/Stilnox 1,714 2,778 2,083 Sanofi-Aventis Insomnia Dec. 16, 1992/June 9, 1987

65 CellCept 1,677

Roche 1,677

Chugai NA

1,535


1,421

Roche 1,421

Chugai 0


Transplant rejection May 3, 1995(U.S. approval)

66 Rebif

Note: Serono wasacquired by MerckKGaA Jan. 5, 2007.

1,670 1,452

(Serono)

1,270

(Serono)

Merck KGaA Multiple sclerosis February 1998

67 Xalatan andXalacom

1,604 1,453 1,372 Pfizer Intraocular pressure June 5, 1996, andsecond-quarter 2001

68 Gemzar 1,592 1,408 1,335 Eli Lilly Cancer May 15, 1996

69 Truvada 1,589 1,194 568 Gilead Sciences HIV infection Aug. 2, 2004

70 Depakote 1,575 1,308 1,096 Abbott Laboratories Seizures March 10, 1983

70 Symbicort 1,575 1,184 1,006 AstraZeneca Asthma August 2000

72 Gardasil 1,481 235 0 Merck & Co. Cervical cancer June 8, 2006

73 Humalog 1,475 1,300 1,198 Eli Lilly Diabetes April 30, 1996

74 Pulmicort 1,454 1,292 1,162 AstraZeneca Asthma June 24, 1997

75 Toprol-XL/Seloken 1,438 1,795 1,735 AstraZeneca Hypertension Jan. 10, 1992/1996

76 Yasmin, Yaz,Yasminelle

Note: 2006 figure ispro forma for Bayerafter Schering AGproductsacquisition as ofJune 23, 2006.

1,429 1,089 803(Schering AG)

Bayer Prevention of pregnancy Yasmin: March 2000(Netherlands approval)

Yaz: March 2006(U.S. approval)

Yasminelle: August 2005(Netherlands approval)

77 Betaseron/Betaferon

Notes: Bayer 2006figure is pro formaafter Schering AGproducts acquisitionas of June 23, 2006.

Chiron was acquiredby Novartis in April2006.

1,409

Bayer 1,409

Novartis NA

1,402

Bayer 1,359

Chiron 43(estimate thruApril 2006)

1,214

Schering 1,072

Chiron 142

Bayer and Novartis Multiple sclerosis July 23, 1993/Nov. 30, 1995

78 Keppra 1,407 1,043 768 UCB Seizures Nov. 30, 1999

79 Flomax 1,399 1,264 989 Boehringer Ingelheim Benign prostatichypertrophy

Oct. 8, 1997

80 Imitrex/Imigran 1,370 1,422 1,394 GlaxoSmithKline Migraine Dec. 28, 1992/1990

81 Pegasys


1,364


1,223


1,169



Hepatitis C June 21, 2002


10/69


10

Rank2007 Medicine






82 Erbitux 1,336

Bristol-MyersSquibb 692

Merck KGaA 644

1,114


Merck KGaA 462

712


Merck KGaA 299

Bristol-Myers Squibband Merck KGaA

Colorectal cancer Feb. 12, 2004

83 Casodex 1,335 1,206 1,123 AstraZeneca Prostate cancer Oct. 4, 1995

84 Kaletra 1,325 1,135 1,005 Abbott Laboratories HIV infection March 9, 2001

85 Zometa 1,297 1,283 1,224 Novartis Hypercalcemia Aug. 21, 2000

86 Neupogen 1,277 1,213 1,216 Amgen Neutropenia Feb. 20, 1991

87 Evista 1,265

Eli Lilly 1,091

Chugai 137

Daiichi 37

1,178

Eli Lilly 1,045

Chugai 115

Daiichi 18

1,115

Eli Lilly 1,036

Chugai 79

Daiichi 0

Eli L illy,ChugaiPharmaceutical,Daiichi Sankyo

Osteoporosis Dec. 9, 1997

88 Flovent/Flixotide 1,242 1,318 1,276 GlaxoSmithKline Asthma March 27, 1996/March 13, 1995

89 Atripla (efavirenz) 1,238

Gilead 903(Atripla)

Bristol-MyersSquibb 335(efavirenz)

281

Gilead 206(Atripla)

Bristol-MyersSquibb 75(efavirenz)

0 Gilead Sciences andBristol-Myers Squibb

HIV infection July 12, 2006

90 Harnal 1,224 1,270 1,378 Astellas Pharma Benign prostatichypertrophy

July 1992

91 Lucentis

Note: Genentechreports U.S. sales thatare also recordedby parent companyRoche

1,219

Roche 826(includesGenentech 815)

Novartis 393

417


Novartis 19

0 Roche,Genentech,Novartis

Wet age-related maculardegeneration

June 30, 2006

92 Botox 1,212 982 831 Allergan Cervical dystonia Dec. 29, 1989

93 Pravacholand Mevalotin(pravastatin)

1,192

BMS 443(Pravachol)

Daiichi 749(Mevalotin/pravastatin)

2,132

BMS 1,197(Pravachol)

Daiichi 935(Mevalotin/pravastatin)

3,688

BMS 2,256(Pravachol)

Daiichi 1,432(Mevalotin/pravastatin)

Bristol-Myers Squibband Daiichi Sankyo

Cholesterol Oct. 31, 1991, and 1988

94 Detrol and Detrol LA 1,190 1,100 988 Pfizer Overactive bladder March 25, 1998, andDec. 22, 2000

95 Coreg 1,174 1,558 1,146 GlaxoSmithKline Hypertension Sept. 14, 1995

96 Duragesic/FentanylTransdermal

1,164 1,295 1,585 Johnson & Johnson Pain Duragesic: Aug. 7, 1990

97 Synagis

Notes: MedImmunewas acquired byAstraZeneca inJune 2007.

Abbott completedthe U.S. jointpromotion ofSynagis inDecember 2006;Abbott recordedU.S. joint-promotionrevenue.

1,161(estimate)AstraZeneca 618

MedImmune

543 (First-half2007 estimate)

Abbott 0

DainipponSumitomo 0

1,438

AstraZeneca 0

MedImmune1,065

Abbott 373

DainipponSumitomo 0

1,414

AstraZeneca 0

MedImmune1,063

Abbott 231

DainipponSumitomo 120

AstraZeneca Respiratory syncytial virus June 19, 1998


11/69

11


Rank2007 Medicine






98 Cialis

Note: Eli Lillyacquired all ofthe outstandingcommon stockof Icos, thecompanys partner

in the Lilly Icosjoint venture for themanufacture andsales of Cialis, asof Jan. 29, 2007.

1,144Eli Lilly 1,144

Lilly Icos 0

971

Lilly Icos 755

Eli Lilly 216

747Lilly Icos 577

Eli Lilly 170

Eli Lilly Erect ile dysfunction Nov. 14, 2002

99 Prilosec/Losec 1,143 1,371 1,652 AstraZeneca Gastrointestinal disorders Sept. 14, 1989/1987

100 Zosyn/Tazocin 1,137 972 892 Wyeth Bacterial infections Oct. 22, 1993/Dec. 18, 1995

101 Cerezyme 1,130 1,007 932 Genzyme Gauchers disease April 5, 1991

102 Reyataz 1,124 931 696 Bristol-Myers Squibb HIV infection Jan. 6, 2003

103 Kogenate 1,121 1,079 909 (Bayer) Bayer Hemophilia Feb. 25, 1993

104 Wellbutrin XL 1,120

GlaxoSmithKline908

Biovail 212

2,046

GlaxoSmithKline1,596

Biovail 450

1,648

GlaxoSmithKline1,294

Biovail 354

GlaxoSmithKline andBiovail

Depression Aug. 28, 2003

105 Paxil/Seroxat 1,106 1,240 1,230 GlaxoSmithKline Depression Dec. 29, 1992/October 1998

106 Zoladex 1,104 1,008 1,004 AstraZeneca Prostate cancer Dec. 29, 1989

107 Nasonex 1,092 944 737 Schering-Plough Allergic rhinitis Oct. 1, 1997

108 Infanrix and Pediarix 1,086 1,022 862 GlaxoSmithKl ine Diphther ia, tetanus, andpertussis

January 1996 andDec. 13, 2002

109 NovoSeven 1,078 1,036 931 Novo Nordisk Bleeding due tohemophilia

Feb. 23, 1996

110 Boniva/Bonviva 1,061

Roche 739

GlaxoSmithKline

322

597

Roche 407

GlaxoSmithKline

190

108

Roche 72

GlaxoSmithKline

36

Roche andGlaxoSmithKline

Osteoporosis March 24, 2005/February 2004

111 Augmentin 1,060 1,140 1,332 GlaxoSmithKline Bacterial infections Aug. 6, 1984

112 GlaxoSmithKlinehepatitis vaccines(primarily Engerix-B,Havrix, Twinrix)

1,058 958 888 GlaxoSmithKline Hepatitis Aug. 28, 1989,Feb. 22, 1995,September 1996

113 Premarin, Prempro,Premphase

1,055 1,051 909 Wyeth Menopausal symptoms 1942, Nov. 17, 1995,Nov. 17, 1995

114 Tarceva

Note: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent companyRoche.

1,054

Roche 885(includesGenentech 417and Chugai 3)

OSI 169

833


OSI 155

408


OSI 85

Roche,Genentech,ChugaiPharmaceutical,OSI Pharmaceuticals

Non-small cell lung cancer Nov. 18, 2004

115 Adderall XR 1,031 864 731 Shire PharmaceuticalsGroup

Attention-deficithyperactivity disorder

Oct. 11, 2001

116 Concerta 1,028 930 774 Johnson & Johnson Attention-deficithyperactivity disorder

Aug. 1, 2000

117 Sandostatin 1,027 915 896 Novartis Acromegaly Oct. 21, 1988

118 Delix and Tritace 1,016 1,340 1,383 Sanofi-Aventis Hypertension July 7, 2000, andJuly 6, 2000

119 Avelox/Avalox 1,013

Bayer 610

Schering-Plough384

Shionogi 19

871

Bayer 543

Schering-Plough304

Shionogi 24

745

Bayer 499

Schering-Plough228

Shionogi 18

Bayer,Schering-Plough,Shionogi

Bacterial infections Dec. 10, 1999/June 21, 1999


12/69


12

Rank2007 Medicine






120 Humulin 985 925 1,005 Eli Lilly Diabetes Oct. 28, 1982

121 Tracleer 983 749 528 Actelion Pulmonary arterialhypertension

Nov. 20, 2001

122 Camptosar 969 903 910 Pfizer Colorectal cancer June 14, 1996

123 Allegra/Telfast 968 943 1,844 Sanofi-Aventis Allergic rhinitis July 25, 1996/Dec. 3, 1996

124 Byetta 967Amylin 636

Eli Lilly 331

649Amylin 430

Eli Lilly 219

150Amylin 75

Eli Lilly 75

AmylinPharmaceuticalsandEli Lilly

Type 2 diabetes April 28, 2005

125 Xeloda

Note: Chugai reportsJapan sales thatare also recordedby parent companyRoche.

959Roche 959(includesChugai 23)




Cancer 1998

126 Femara

Note: Chugai reportsJapan sales thatare also recorded

by parent companyRoche.

945

Novartis 937

Roche 9

(via Chugai 9)

722

Novartis 719

Roche 3

(via Chugai 3)

536

Novartis

Roche/Chugai 0

Novartis,Roche,ChugaiPharmaceutical

Breast cancer July 25, 1997

127 Neoral andSandimmun

944 918 953 Novartis Transplant rejection July 14, 1995, andNov. 14, 1983

127 Zyvox 944 782 618 Pfizer Bacterial infections April 18, 2000

129 Ortho hormonalcontraceptives

925 1,016 1,136 Johnson & Johnson Contraception NA

130 PegIntron 911 837 751 Schering-Plough Hepatitis C May 25, 2000

131 Combivir 910 1,056 1,166 GlaxoSmithKline HIV infection Sept. 26, 1997

132 Combivent 887 920 769 Boehringer Ingelheim Chronic obstructivepulmonary disease

Oct. 24, 1996

133 Mirapex/Sifrol 883 735 595 Boehringer Ingelheim Parkinsons disease July 1, 1997/Oct. 14, 1997

133 Chantix/Champix 883 101 0 Pfizer Smoking cessation May 10, 2006/Sept. 29, 2006

135 Zocor 877 2,803 4,382 Merck & Co. Cholesterol Dec. 23, 1991

136 Temodar 861 703 588 Schering-Plough Brain tumors Aug. 11, 1999

137 Varivax 855 328 NA Merck & Co. Chickenpox March 17, 1995

138 Geodon/Zeldox 854 758 589 Pfizer Schizophrenia Feb. 5, 2001/May 2002

138 Alimta 854 612 463 Eli Lilly Non-small cell lung cancer Feb. 4, 2004

140 Provigil 852 735 513 Cephalon Sleepiness Dec. 24, 1998

141 Genotropin 843 795 808 Pfizer Growth failure Aug. 24, 1995

142 Adalat 842 901 904 Bayer Hypertension Nov. 27, 1985

143 Namenda 830 660 508 Forest Laboratories Alzheimers disease Oct. 16, 2003

144 Clarinex/Aerius 799 722 646 Schering-Plough Allergic rhinitis Dec. 21, 2001/Jan. 15, 2001

145 Trusopt and Cosopt 787 697 617 Merck & Co. Intraocular pressure Dec. 9, 1994, andApril 7, 1998

146 Revlimid 774 321 3 Celgene Multiple myeloma,myelodysplastic syndrome

Dec. 27, 2005

147 Merrem 773 604 505 AstraZeneca Bacterial infections June 21, 1996

148 Primaxin 764 705 740 Merck & Co. Bacterial infections Nov. 26, 1985

149 Ultane/Sevorane 759 799 874 Abbott Laboratories Anesthesia June 7, 1995/1994

150 Lotrel 748 1,352 1,075 Novartis Hypertension June 16, 1999

151 Voltaren group 747 690 689 Novartis Pain July 28, 1998

152 Biaxin 724 816 1,065 Abbott Laboratories Bacterial infections Oct. 31, 1991

153 Forteo 709 594 389 Eli Lilly Osteoporosis Nov. 26, 2002


13/69

13


Rank2007 Medicine






154 Lidoderm 706 567 419 EndoPharmaceuticalsHoldings

Pain March 19, 1999

155 Vesicare 701Astellas 601

GlaxoSmithKline100

426Astellas 362

GlaxoSmithKline64

174Astellas 148

GlaxoSmithKline26

Astellas Pharma andGlaxoSmithKline

Overactive bladder July 9, 2004

156 Comtan/Comtressand Stalevo

695

Novartis 420(Comtan/Stalevo group)

Orion 275(Stalevo 174 andComtan/Comtess 101)

585



477



Novartis and Orion Parkinsons disease Oct. 19, 1999/Sept. 16, 1998 andJune 11, 2003

157 Trileptal 692 721 615 Novartis Seizures November 1999

157 Requip 692 536 312 GlaxoSmithKline Parkinsons disease Sept. 19, 1997

159 Januvia 668 43 0 Merck & Co. Type 2 diabetes Oct. 16, 2006

160 Lescol group 665 725 767 Novartis Cholesterol Dec. 31, 1993

161 Niaspan

Notes: Abbottacquired KosPharmaceuticalsalong with Niaspanin December 2006.

Kos 2006 figure isa full-year estimatebased on Niaspannine-month 2006sales.

658(Abbott)

498(estimate)

435(Kos)

Abbott Laboratories Cholesterol July 28, 1997

162 Renagel


652

Genzyme 603

Roche 49(via Chugai 49)

559

Genzyme 515


457

Genzyme 418


Genzyme,Roche,ChugaiPharmaceutical

Hyperphosphatemia Oct. 30, 1998

163 Epzicom/Kivexa 648 482 236 GlaxoSmithKline HIV infection Aug. 2, 2004/December 2004

164 Altace 646 653 554 King Pharmaceuticals Cardiovascular events Jan. 28, 1991

165 Norditropin 645 608 511 Novo Nordisk Growth hormonedeficiency

1997

166 GlaxoSmithKlineinfluenza vaccines(primarily Fluarixand FluLaval/Fluviral)

640 340 NA GlaxoSmithKline Influenza Aug. 31, 2005, andOct. 5, 2006/Sept. 10, 2004

167 Amlodin 636 592 568 Dainippon Sumitomo Hypertension, anginapectoris

NA

168 Exelon 632 525 467 Novartis Alzheimers disease May 12, 1998

168 Vfend 632 515 397 Pfizer Fungal infections March 21, 2002170 Sustiva 621 715 680 Bristol-Myers Squibb HIV infection Sept. 17, 1998

171 Viread 613 689 779 Gilead Sciences HIV infection Oct. 26, 2001

171 Xolair

Note: Genentechreports U.S. salesthat are alsorecorded by parentcompany Roche.

613


Novartis 140

550


Novartis 102

345


Novartis 5

Roche,Genentech,Novartis

Asthma June 20, 2003

173 Gaster 609 622 688 Astellas Pharma Gastrointestinal disorders 1985

174 Lunesta 601 565 327 Sepracor Insomnia Dec. 15, 2004

175 Lamisil group 595 978 1,133 Novartis Fungal infections Dec. 30, 1992


14/69


14

Rank2007 Medicine






175 Gonal-f

Note: Serono wasacquired by MerckKGaA Jan. 5, 2007.

595 533(Serono)

547(Serono)

Merck KGaA Infertility Oct. 20, 1995

177 Avandamet 584 408 350 GlaxoSmithKline Type 2 diabetes Oct. 10, 2002

178 Sutent 581 219 0 Pfizer Cancer Jan. 26, 2006

179 Avodart 570 432 258 GlaxoSmithKline Benign prostatichyperplasia

Nov. 20, 2001

179 Follistim/Puregon

Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences alongwith Follistim/PuregonNov. 19, 2007.

Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughs

sales are an actualfigure for the re-mainder of 2007.

570(estimate)

Akzo Nobel 513(estimate)

Schering-Plough57

527(Akzo Nobel)

487(Akzo Nobel)

Akzo Nobel andSchering-Plough

Infertility Sept. 29, 1997/May 3, 1996

181 Strattera 569 579 552 Eli Lilly Attention-deficithyperactivity disorder

Nov. 26, 2002

182 Caduet 568 370 185 Pfizer Cholesterol andhypertension

Jan. 30, 2004

183 Levitra 553Bayer 455

GlaxoSmithKline98

517

Bayer 431

GlaxoSmithKline86

436

Bayer 356

GlaxoSmithKline80

Bayer andGlaxoSmithKline

Erectile dysfunction March 6, 2003

184 Serevent 538 582 660 GlaxoSmithKline Asthma Feb. 4, 1994

185 Amaryl 537 618 928 Sanofi-Aventis Type 2 diabetes Nov. 30, 1995

185 Cancidas 537 530 570 Merck & Co. Fungal infections Jan. 26, 2001187 Synthroid 533 534 554 Abbott Laboratories Hypothyroidism 1955

188 Zoloft 531 2,110 3,256 Pfizer Depression Dec. 30, 1991

189 Basen 528 557 636 TakedaPharmaceutical

Hyperglycemia 1994

190 Xenical 527 578 529 Roche Obesity July 29, 1998

191 RotaTeq 525 163 0 Merck & Co. Rotavirus gastroenteritis Feb. 3, 2006

191 Cipro/Ciprobay 525

Bayer 525

Schering-PloughNA

814

Bayer 703

Schering-Plough111

866

Bayer 720

Schering-Plough146

Bayer Bacter ial infect ions Oct. 22, 1987/1987

193 Relenza 524 182 NA GlaxoSmithKline Influenza June 1999

194 Concor (bisoprolol) 520 497 478 Merck KGaA Hypertension July 31, 1992195 Cardura 506 538 586 Pfizer Hypertension Nov. 2, 1990

196 Vasotec andVaseretic

495 547 623 Merck & Co. Hypertension Dec. 24, 1985, andDec. 24, 1985

196 Mirena

Note: 2006 figure ispro forma for Bayerafter Schering AGproducts acquisitionas of June 23, 2006.

495 413 333(Schering AG)

Bayer Contraception Dec. 6, 2000

198 Xopenex InhalationSolution

487 543 411 Sepracor Bronchospasm March 25, 1999


15/69

15


Rank2007 Medicine






199 Claritin 481Schering-Plough391

Shionogi 90

428Schering-Plough356

Shionogi 72

451Schering-Plough371

Shionogi 80

Schering-Plough andShionogi

Allergic rhinitis April 12, 1993

200 Maxalt 467 406 348 Merck & Co. Migraine June 30, 2002

201 Trizivir 466 536 606 GlaxoSmithKline HIV infection Nov. 14, 2000

202 Sensipar 463 321 157 Amgen Hypercalcemia March 8, 2004

203 Tysabri 462Biogen Idec 230

Elan 232

64Biogen Idec 36

Elan 28

16Biogen Idec 5

Elan 11

Biogen Idec andElan

Multiple sclerosis Nov. 23, 2004

204 Xatral 457 484 450 Sanofi-Aventis Benign prostatichypertrophy

January 2000

205 Valcyte andCymevene

452 407 328 Roche Cytomegalovirus retinitis March 29, 2001, and NA

206 Thalomid 447 433 388 Celgene Erythema nodosumleprosum

July 16, 1998

207 Humatrope 441 416 414 Eli Lilly Growth failure March 9, 1991

208 Skelaxin 440 415 345 King Pharmaceuticals Musculoskeletal conditions NA209 Zithromax and Zmax 438 638 2,025 Pfizer Bacter ial infect ions Nov. 4, 1991, and

June 10, 2005

210 Zomig 434 398 352 AstraZeneca Migraine July 8, 1997

211 Depakine 433 413 436 Sanofi-Aventis Epilepsy NA

211 BeneFix 433 358 343 Wyeth Hemophilia Feb. 11, 1997

213 Neurontin 431 496 639 Pfizer Seizures Dec. 29, 1993

214 Mobic 428Boehringer 326

Daiichi 102

901

Boehringer 794

Daiichi 107

2,501

Abbott 1,232

Boehringer 1,163

Daiichi Sankyo106

Boehringer IngelheimandDaiichi Sankyo

Osteoarthritis andrheumatoid arthritis

Feb. 27, 1996

215 Fabrazyme 424 359 305 Genzyme Fabrys disease August 2001

215 Nutropin andNutropin AQ

Note: Genentechreports U.S. sales thatare also recordedby parent companyRoche.

424Roche 392(includesGenentech 371)

Ipsen 32(Nutropin AQonly)





Roche,Genentech,Ipsen

Growth failure Nutropin: Nov. 17, 1993(U.S. approval)

Nutropin AQ: Dec. 29,1995 (U.S. approval)

217 Taxol 422 563 747 Bristol-Myers Squibb Cancers Dec. 29, 1992

217 Androgel 422 377 328 Solvay Hypogonadism June 14, 2000(U.S. approval)

219 Diflucan 415 435 498 Pfizer Fungal infections Jan. 29, 1990

220 Magnevist

Note: 2006 figure ispro forma for Bayerafter Schering AGproducts acquisitionas of June 23, 2006.

413 443 450(Schering)

Bayer Magnetic resonanceimaging

June 2, 1988

220 Tegretol 413 391 393 Novartis Seizures March 12, 1972

222 Proscar 411 619 741 Merck & Co. Benign prostatichypertrophy

June 19, 1992

223 Glucobay 409 422 404 Bayer Type 2 diabetes NA

224 Propecia 405 352 292 Merck & Co. Hair loss Dec. 19, 1997

225 Nasacort 403 388 381 Sanofi-Aventis Allergic rhinitis May 21, 2000

225 Pletal 403 360 NA OtsukaPharmaceutical

Cardiac ischemiccomplications

1988 (Japan approval)


16/69


16

Rank2007 Medicine






225 Pulmozyme

Note: Genentechreports U.S. sales thatare also recordedby parent companyRoche.

403


363


328


Roche andGenentech

Cystic fibrosis Dec. 30, 1993

228 Aromasin 401 320 247 Pfizer Breast cancer Oct. 21, 1999229 Flonase/Flixonase 398 622 1,312 GlaxoSmithKline Allergic rhinitis Oct. 9, 1994/

Sept. 15, 1995

230 Prandin andNovoNorm

395 365 306 Novo Nordisk Type 2 diabetes Prandin: Dec. 22, 1997(U.S. approval)NovoNorm:Aug. 17, 1998(EU approval)

231 Zofran 392 1,694 1,674 GlaxoSmithKline Nausea and vomiting Dec. 31, 1992

231 Lumigan franchise 392 328 268 Allergan Intraocular pressure March 16, 2001

233 Abraxane 387

Abraxis 325

AstraZeneca 62

193

Abraxis 175

AstraZeneca 18

134

Abraxis 134

AstraZeneca 0

Abraxis andAstraZeneca

Breast cancer February 2005(U.S. launch)

233 NuvaRing

Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences alongwith NuvaRingNov. 19, 2007.

Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughssales are an actualfigure for the re-mainder of 2007.

387(estimate)

Akzo Nobel 342(estimate)Schering-Plough45

292

(Akzo Nobel)174(Akzo Nobel)


Contraception June 12, 2001

235 Aggrenox 381 308 236 Boehringer Ingelheim Stroke Nov. 22, 1999

235 Ritalin and Focalin 381Novartis 375

Celgene 6

337Novartis 330

Celgene 7

212Novartis 208

Celgene 4

Novartis and Celgene Attention-deficithyperactivity disorder

Dec. 5, 1955, andNov. 13, 2001

237 Adenoscan 376 371 353 Astellas Pharma Myocardial perfusionscintigraphy

May 19, 1999

238 Opalmon 373 338 326 Ono Pharmaceutical Thromboangiitis obliterans 1988

239 Nexavar 370

Bayer 370

Onyx NA

178

Bayer 178

Onyx NA

NA

Bayer NA

Onyx NA

Bayer andOnyxPharmaceuticals

Advanced kidney cancerand liver cancer

Dec. 21, 2005(U.S. launch)

240 Restasis 369

Allergan 345

Inspire 24

286

Allergan 270

Inspire 16

198

Allergan 191

Inspire 7

Allergan andInspirePharmaceuticals

Dry eye Dec. 23, 2002

241 Fraxiparine 368 408 422 GlaxoSmithKline Deep-vein thrombosis NA

242 Rapamune 365 337 300 Wyeth Renal transplant rejection Sept. 15, 1999

242 Glucophage/metformin franchise

365Merck KGaA 365(Glucophage/metforminproducts)

BMS NA(Glucophagefranchise)

493(estimate)

Merck KGaA 398(Glucophage/metforminproducts)

BMS 95(estimate forGlucophagefranchise)

579

Merck KGaA 407(Glucophage/metforminproducts)

BMS 172(Glucophagefranchise)

Merck KGaA andBristol-Myers Squibb

Type 2 diabetes Dec. 29, 1994


17/69

17


Rank2007 Medicine






244 Foradil 362 331 332 Novartis Asthma Nov. 17, 1999

245 Zovirax 361

GlaxoSmithKline214

Biovail 147

352

GlaxoSmithKline240

Biovail 112

358

GlaxoSmithKline262

Biovail 96


Herpes March 30, 1986

246 Viramune 359 378 395 Boehringer Ingelheim HIV infection June 22, 2000

246 rhBMP-2 359 308 236 Wyeth Tibia fractures Sept. 17, 2002

248 Exjade 357 143 2 Novartis Iron overload Nov. 2, 2005(U.S. approval)

249 Espo and NESP 356 344 368 Kirin Brewery Anemia Espo: 1990(Japan launch)

NESP: 2007(Japan launch)

250 Rhinocort 354 360 387 AstraZeneca Allergic rhinitis Feb. 14, 1994

250 Kytril

Note: Chugai reportsJapan sales thatare also recordedby parent company

Roche.

354

Roche 354(includesChugai 116)

415


417



Nausea and vomiting January 1992

252 Mucosta 353 339 NA OtsukaPharmaceutical

Gastritis and ulcers 1990 (Japan launch)

253 Alphagan P,Alphagan,Combigan

341 296 277 Allergan Intraocular pressure March 16, 2001,Sept. 6, 1996,fourth-quarter 2003

254 AmBisome 339

Gilead 263

Astellas 76

311

Gilead 223

Astellas 88

310

Gilead 221

Astellas 89

Gilead Sciences andAstellas Pharma

Fungal infections Aug. 11, 1997

255 Neutrogin

Note: Chugai reportsJapan sales thatare also recordedby parent company

Roche.

338


316


303



Neutropenia Oct. 4, 1991

256 Zeffix 336 324 290 GlaxoSmithKline Hepatitis B Dec. 8, 1998

256 Loxonin 336 309 290 Daiichi Sankyo Inflammation Feb. 17, 1978

256 Zantac 336 464(GSK)

495

GSK 488

Daiichi Sankyo 7

GlaxoSmithKline Gastrointestinal disorders June 9, 1983

259 ReFacto 335 306 268 Wyeth Hemophilia April 14, 2003

260 Rocephin

Note: Chugai reportsJapan sales thatare also recordedby parent companyRoche.

333


347


773



Bacterial infections Dec. 21, 1984


18/69


18

Rank2007 Medicine






261 Integrilin

Notes:Schering-Ploughis marketer in U.S.and other non-EUareas.

Millenniumreportedco-promotionrevenue from Jan.1, 2005, throughSept. 1, 2005;thereafter royaltyand strategicalliance revenuewere recorded.

GlaxoSmithKline isEU marketer.

332

Schering-Plough332Millennium NA

GlaxoSmithKline

NA

329

Schering-Plough329

Millennium NA

GlaxoSmithKline

NA

439

Schering-Plough315

Millennium 124

GlaxoSmithKline

NA

Schering-Plough,MillenniumPharmaceuticals,GlaxoSmithKline

Acute coronary syndrome June 1998 (U.S. launch)

262 Arcoxia 329 265 218 Merck & Co. Osteoarthritis andrheumatoid arthritis

April 15, 2002

263 Xanax andXanax XR

325 316 409 Pfizer Anxiety disorder andpanic disorder

Nov. 27, 1985, andJan. 17, 2003

264 Ultravist


322 304 340(Schering AG) Bayer Imaging/various May 11, 1999

264 Decapeptyl 322 304 289 Ipsen Advanced metastaticprostate cancer

1986 (France launch)

266 Activase, TNKase,Cathflo Activase

Note: Genentechreports U.S. salesthat are recordedby parent companyRoche.

318


302


258


Roche andGenentech

Myocardial infarction Feb. 17, 1996,June 2, 2000, andSept. 4, 2001

267 Relpax 315 286 233 Pfizer Migraine June 14, 2001

268 Epivir 312 404 522 GlaxoSmithKline HIV infection Nov. 17, 1995

268 Omnipaque 312 315 347 Daiichi Sankyo Contrast enhancement Dec. 26, 1985(U.S. approval)

270 Venofer 311 309 226 Daiichi Sankyo Iron deficiency anemia Nov. 7, 2000

271 Crixivan and Stocrin 310 327 348 Merck & Co. HIV infection March 13, 1996,and 1999

272 Tenormin 308 320 352 AstraZeneca Hypertension Aug. 19, 1981

273 Ebixa 304 250 203 H. Lundbeck Alzheimers disease May 23, 2002

273 Remeron

Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences along

with RemeronNov. 19, 2007.

Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughssales are an actualfigure for the re-mainder of 2007.

304(estimate)


Schering-Plough

33

347(Akzo Nobel)

388(Akzo Nobel)


Depression June 15, 2000

275 Hepsera 303 231 187 Gilead Sciences Hepatitis B Sept. 20, 2002

276 Zestril 295 307 332 AstraZeneca Hypertension Dec. 30, 1987


19/69

19


Rank2007 Medicine






277 Iopamiron


289 303 332(Schering)

Bayer Imaging/uroangiography NA

278 Flomox 286 306 341 Shionogi Bacterial infections June 1997279 Cubicin 285 190 113 Cubist

PharmaceuticalsBacterial infections Sept. 12, 2003

280 Agenerase andLexiva

282 262 224 GlaxoSmithKline HIV infection April 15, 1999, andOct. 20, 2003

281 Miacalcin/Miacalcic

281 339 365 Novartis Osteoporosis July 3,1986/NA

282 Vaqta,Recombivax HB,Comvax

280 249 195 Merck & Co. Hepatitis Vaqta: May 1996(U.S. launch)Recombivax HB:Aug. 27, 1999(U.S. approval)Comvax: January 1997(U.S. launch)

283 Radicut 279 286 325 Mitsubishi TanabePharma

Cerebral infarction June 2001(Japan launch)

284 Rebetol 277 311 331 Schering-Plough Hepatitis C June 4, 2002

285 Baraclude 275 83 12 Bristol-Myers Squibb Hepatitis B March 29, 2005

286 Tobi/Tobramycin

Note: Chiron andTobi were acquiredby Novartis in April2006.

273(Novartis)

245Novartis 177

Chiron 68(estimate)

233(Chiron)

Novartis Cystic fibrosis infection Tobi: Dec. 22, 1997(U.S. approval)

287 Onon 271 268 265 Ono Pharmaceutical Bronchial asthma andallergic rhinitis

Oct. 1, 1999

287 Plendil 271 275 360 AstraZeneca Hypertension July 27, 1995

287 Creon 271 262 222 Solvay Pancreatic exocrineinsufficiency

NA

290 Fuzeon 267 249 208 Roche HIV infection March 27, 2003(U.S. launch)

290 Thrombin-JMI 267 247 221 King Pharmaceuticals Bleeding during surgery Feb. 24, 1995

292 Velcade

Note: Millenniumfigures are netproduct sales andexclude strategicalliance revenueand royaltiesassociated withnon-U.S. marketer,J&Js OrthoBiotech.

265

Millennium 265

J&J NA

221

Millennium 221

J&J NA

192

Millennium 192

J&J NA

MillenniumPharmaceuticalsandJohnson & Johnson

Multiple myeloma May 13, 2003(U.S. approval)

293 ProQuad 264 235 NA Merck & Co. Measles, mumps, rubella Sept. 6, 2005

294 Diprivan

Note: Abraxis

acquired U.S. rightsto Diprivan fromAstraZeneca inJune 2006.

263+

AstraZeneca 263

Abraxis NA

304+

AstraZeneca 304

Abraxis NA

369(AstraZeneca)

AstraZeneca andAbraxis

Anesthesia Oct. 2, 1989

295 DuoNeb

Note: MerckKGaAs Dey LPalong with DuoNebwere acquired Oct.2, 2007, by Mylan;DuoNeb productexclusivity was lostin July 2007.

260(estimate)

Merck KGaA 218(estimate)

Mylan 42(estimate)

369(Merck KGaA)

344(Merck KGaA)

Merck KGaA andMylan

Bronchospasm March 21, 2001

296 Caelyx 257 206 181 Schering-Plough Cancers June 21, 1996


20/69


20

Rank2007 Medicine






297 Zanidip/Lercadip/lercanidipine

256 235 194 Recordati Hypertension NA

298 Clarith 255 273 275 TaishoPharmaceutical

Bacterial infections NA

298 Angiomax 255 201 150 The Medicines Co. Percutaneous coronaryinterventions

January 2001(U.S. launch)

300 Coniel 254 263 281 Kyowa Hakko Kogyo Hypertension NA

301 Urso franchise 248

MitsubishiTanabe 171

Axcan 77

221

MitsubishiPharma 159

Axcan 62

223

MitsubishiPharma 176

Axcan 47

Mitsubishi TanabePharma andAxcan Pharma

Primary bil iary cirrhosis July 1962 (Japan)May 1998 (U.S. launch)

302 Synvisc 242 234 219 Genzyme Osteoarthritis Aug. 13, 1997

303 Actiq 240 578 412 Cephalon Cancer pain Nov. 4, 1998

303 Diane


240 240 236(Schering AG)

Bayer Contraception NA

305 Iressa 238 237 273 AstraZeneca Nonsmall cell lung cancer May 5, 2003

305 Hycamtin 238 226 198 GlaxoSmithKline Cancers May 29, 2000

307 Zostavax 236 39 0 Merck & Co. Shingles May 25, 2006

308 Omnicef 235 637 495 Abbott Laboratories Bacterial infections Dec. 4, 1997

309 Intron A 233 237 287 Schering-Plough Hepatitis June 5, 1990

309 Allelock 233 210 199 Kyowa Hakko Kogyo Allergic rhinitis Dec. 22, 2000

311 Orencia 231 89 0 Bristol-Myers Squibb Rheumatoid arthritis Dec. 23, 2005

312 Xyzal 230 196 173 UCB Allergic rhinitis Aug. 28, 2001

313 M-M-R II 228 NA NA Merck & Co. Measles, mumps, andrubella

NA

314 WelChol 227 187 148 Daiichi Sankyo Cholesterol May 27, 2004

315 Saizen

Note: Merck KGaAacquired Seronoalong with SaizenJan. 5, 2007.

224 209(Serono)

206(Serono)

Merck KGaA Growth failure Oct. 8, 1996

316 Subutex/Subuxone 220 203 197 Schering-Plough Opiate addiction Oct. 8, 2002(U.S. approvals)

317 Ziagen 218 234 272 GlaxoSmithKline HIV infection Dec. 17, 1998

318 Aloxi 216(estimate)

251 249 MGI Pharma Nausea and vomiting July 25, 2003

319 Visudyne 215 354 484 Novartis Age-related maculardegeneration

April 12, 2000

319 Myslee 215 194 171 Astellas Pharma Insomnia Dec. 13, 2000

321 Faslodex 214 186 140 AstraZeneca Breast cancer April 25, 2002

322 Raptiva

Notes: Total2007, 2006 and2005 figureswere reported byRaptiva developerXoma.

Genentech reportsU.S. sales that arerecorded by parentcompany Roche.

Merck KGaAacquired SeronoJan. 5, 2007.

213

Roche 107 (viaGenentech 107)

Merck KGaA106

160


Serono 70

113


Serono 34

Genentech andMerck KGaA

Psoriasis November 2003(U.S. launch)

323 Artist 211 193 182 Daiichi Sankyo Congestive heart failure NA


21/69

21


Rank2007 Medicine






324 Serc 206 200 167 Solvay Menieres Syndrome NA

325 Emend 204 131 87 Merck & Co. Nausea and vomiting March 26, 2003

325 Vancocin 204 167 126 ViroPharma Bacterial infections April 15, 1986(U.S. approval)

327 Coumadin 201 220 212 Bristol-Myers Squibb Deep-vein thrombosis NA

327 Myozyme 201 59 4 Genzyme Pompe disease NA

327 Remodulin 201 153 110 United Therapeutics Pulmonary arterialhypertension

May 21, 2002(U.S. launch)

327 Livial

Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences alongwith LivialNov. 19, 2007.

Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughs

sales are an actualfigure for the re-mainder of 2007.

201(estimate)


Schering-Plough24

207(Akzo Nobel)

211(Akzo Nobel)


Menopausal symptoms March 1997

331 Arixtra 200 116 48 GlaxoSmithKline Deep-vein thrombosis Dec. 7, 2001

332 Cefzon 198 255 293 Astellas Pharma Bacterial infections 1991

332 Cardizem LA

Note: Abbottacquired KosPharmaceuticals inDecember 2006

198(estimate)

Abbott 129(estimate)

Biovail 69

162(estimate)

Kos 105(estimate)

Abbott NA

Biovail 57

132

Kos 70

Biovail 62

Abbott Laboratoriesand Biovail

Hypertension Feb. 6, 2003

334 Amitiza 196(Takeda)

57(Takeda)

0 TakedaPharmaceuticaland Sucampo

Pharmaceuticals

Constipation April 25, 2006(U.S. launch)

335 Gasmotin 195 185 163 Dainippon Sumitomo Gastrointestinal disorders 1998

335 Hyalein 195 179 169 SantenPharmaceutical

Corneal disease June 1995(Japan launch)

337 Invanz 190 139 94 Merck & Co. Bacterial infections Nov. 9, 2001

337 Timoptic/Timoptoland Timoptic-XE/Timoptol XE

190

Merck & Co. 120(Timoptic andTimoptic XE)

Santen 70(Timoptol andTimoptol XE)

198



211



Merck & Co. andSantenPharmaceutical

Intraocular pressure andglaucoma

Timoptic: Aug. 17, 1978(U.S. approval)Timoptic-XE: Nov. 4,1993 (U.S. approval)Timoptol: September1981 (Japan launch)Timoptol XE: November1999 (Japan launch)

339 Euthyrox products 186 176 156 Merck KGaA Hypothyroidism NA

340 Anplag 183 167 177 Mitsubishi TanabePharma

Chronic arterial occlusion October 1993 (launch)

341 Rotarix 182 88 NA GlaxoSmithKline Rotavirus infection Feb. 27, 2006

341 Elaprase 182 24 0 Shire PharmaceuticalsGroup

Hunter syndrome July 24, 2006(U.S. approval)

341 Bonalon 182 138 119 Teijin Osteoporosis August 2001(Japan launch)

344 Enablex/Emselex 179 114 46 Novartis Overactive bladder Enablex: Dec. 22, 2004(U.S. appoval)Emselex: Oct. 27, 2004(EU approval)

345 Mycamine/Funguard

178 165 152 Astellas Pharma Fungal infections March 16, 2005/December 2002

346 Dysport 176 155 127 Ipsen Cervical dystonia 1991 (U.K. launch)


22/69


22

Rank2007 Medicine






346 Elidel 176 179 268 Novartis Atopic dermatitis Dec. 13, 2001

346 Herbesser 176 180 188 Mitsubishi TanabePharma

Hypertension February 1974

346 Pentasa 176 138 136 Shire PharmaceuticalsGroup

Ulcerative colitis May 11, 1997

346 Calcichew 176

Nycomed 122

Shire 54

174

Nycomed 128

Shire 46

145

Nycomed 106

Shire 39

Nycomed and

Shire PharmaceuticalsGroup

Osteoporosis NA

351 Thymoglobulin/Lymphoglobuline

175 150 128 Genzyme Renal transplant rejection Dec. 30, 1998/NA

352 Kinedak 174 173 212 Ono Pharmaceutical Peripheral neuropathy NA

352 Influvac 174 162 137 Solvay Influenza 2003 (launch)

354 Teveten franchise

Notes: Abbottacquired KosPharmaceuticals inDecember 2006.

Biovailtransferredproduct rights forTeveten to Kos inMay 2005.

172(estimate)

Solvay 145

Abbott 27(estimate)

154(estimate)

Solvay 130

Kos 24(estimate)

Abbott NA

153

Solvay 125

Kos 22

Biovail 6

Solvay and AbbottLaboratories

Hypertension Dec. 22, 1997(U.S. approval)

355 Vectibix 170 39 0 Amgen Colorectal cancer Sept. 27, 2006

356 Kadian 168 138 102 Alpharma Pain July 3, 1996

357 Benet 165 162 157 TakedaPharmaceutical

Osteoporosis May 2002(Japan launch)

358 Protopic 164 147 144 Astellas Pharma Dermatitis June 16, 1999

358 Tanakan 164 178 166 Ipsen Neurological and vasculardisorders

1975 (France launch)

360 Sprycel 158 25 0 Bristol-Myers Squibb Leukemia June 28, 2006

361 Tussionex 156 144 148 UCB Cough Dec. 31, 1987

362 Sigmart 153 154 165 ChugaiPharmaceutical

Angina pectoris 1984

363 Ceredist 152 145 137 Mitsubishi TanabePharma

Spinal cerebellardegeneration

September 2000(Japan launch)

364 Azilect 151

Teva 120

Lundbeck 31

57

Teva 44

Lundbeck 13

1+

Teva NA

Lundbeck 1

Teva PharmaceuticalIndustries andH. Lundbeck

Parkinsons disease March 2005(Israel launch)

365 Wellbutrin IR and SR 150

GSK 150

Biovail NA

204

GSK 204

Biovail NA

184

GSK 184

Biovail NA


Depression Dec. 30, 1985, andOct. 4, 1996

365 Eligard 150

Astellas 92

MediGene 30

QLT 28

123

Astellas 59

MediGene 42

QLT 22

70

Astellas 26

MediGene 27

QLT 17

Astellas Pharma,MediGene, QLT

Prostate cancer May 2004(Germany launch)

365 Trasylol 150 210 315 Bayer Perioperative blood loss Dec. 29, 1993

368 Loestrin 24 FE 149 44 0 Warner Chilcott Prevention of pregnancy Feb. 17, 2006(U.S. approval)

369 Meropen 148 143 141 Dainippon Sumitomo Bacterial infections NA

370 Prorenal 145 138 126 Dainippon Sumitomo Peripheral circulat ion 1988

371 Tanatril 144 145 147 Mitsubishi TanabePharma

Hypertension December 1993

371 Replagal 144 118 41 Shire PharmaceuticalsGroup

Fabrys disease Aug. 3, 2001

371 Marinol 144 145 115 Solvay Nausea and vomiting 1987 (U.S. launch)


23/69

23


Rank2007 Medicine






374 Somatuline 142 126 112 Ipsen Acromegaly 1995 (France launch)

375 Durotep 139 141 135 Kyowa Hakko Kogyo Cancer pain October 2001

375 Elcitonin 139 138 152 Asahi Kasei Osteoporosis NA

377 Nootropil 138 136 141 UCB Cognitive disorders NA

377 Tygacil 138 72 10 Wyeth Bacterial infections June 15, 2005

379 Fentora 135 29 0 Cephalon Cancer pain Sept. 25, 2006

380 Boostrix 132 120 NA GlaxoSmithKl ine Diphther ia, tetanus, andpertussis

May 3, 2005

381 Gran 130 134 138 Kirin Brewery Leukopenia 1991 (Japan launch)

382 Venoglobulin-IH 129 132 141 Mitsubishi TanabePharma

Immunological conditions January 1992

383 Taclonex 127 60 0 Warner Chilcott Psoriasis vulgaris April 3, 2006(U.S. launch)

383 Avinza

Note: Kingacquired all rightsto Avinza in theUnited States, itsterritories andCanada fromLigand Feb. 26,2007.

127King 109

Ligand 18

137King 0

Ligand 137

113King 0

Ligand 113

King Pharmaceuticalsand LigandPharmaceuticals

Pain March 20, 2002

385 Actovegin 126 108 88 Nycomed Metabolic stimulation NA

385 Rozerem 126 103 30 TakedaPharmaceutical

Insomnia Sept. 26, 2005(U.S. launch)

387 Isovorin 125 140 128 TakedaPharmaceutical

Tumors October 1999(Japan launch)

387 Onealfa 125 118 120 Teijin Osteoporosis NA

389 Kremezin 124 122 130 Daiichi Sankyo Renal failure December 1991

389 Aldurazyme 124 96 76 BioMarin/Genzyme(joint venture)

Mucopolysaccharidosis April 30, 2003

391 Maxipime 123 160 140 Elan Bacterial infections Jan. 18, 1996

391 Alfarol 123 125 135 ChugaiPharmaceutical

Osteoporosis 1981

391 Seltouch 123 127 137 TakedaPharmaceutical

Pain September 1993(Japan launch)

394 Flumarin 122 133 156 Shionogi Bacterial infections NA

394 Percocet 122 103 111 EndoPharmaceuticalsHoldings

Pain June 25, 1999

394 Smecta 122 110 93 Ipsen Diarrhea and pain 1977 (France launch)

397 Sunrythm 121 117 119 Daiichi Sankyo Arrhythmia NA

398 Frandol 120 123 127 Astellas Pharma Angina pectoris NA

399 Vancomycin 117 117 111 Shionogi Bacterial infections NA

399 Imunace 117 117 111 Shionogi Cancers NA

399 Dacogen 117(estimate)

36 0 MGI Pharma Myelodysplastic syndrome May 26, 2006(U.S. launch)

402 Depas 116 113 126 Mitsubishi TanabePharma

Anxiety March 1984 (launch)

402 Doryx 116 102 96 Warner Chilcott Bacterial infections July 22, 1985(U.S. approval)

404 Palux 114 112 120 TaishoPharmaceutical

Ulcers 1999

405 Ebastel 111 114 113 Dainippon Sumitomo Allergies NA

405 Mucosolvan 111 115 117 Teijin Expectorant NA

407 Luvox 110 111 103 Astellas Pharma Depression April 8, 2003

407 Onon Dry Syrup 110 114 94 Ono Pharmaceutical Pediatric bronchialasthma

Oct. 1, 1999

409 Metadate CD/Equasym XL

108 93 70 UCB Attention-deficithyperactivity disorder

April 3, 2001/February 2005


24/69


24

Rank2007 Medicine






410 Opana andOpana ER

107 7 0 EndoPharmaceuticalsHoldings

Pain July 24, 2006(U.S. launches)

411 Depakene 105 102 102 Kyowa Hakko Kogyo Seizures NA

412 Liple 104 102 113 Mitsubishi TanabePharma

Chronic arterial occlusion November 1988(launch)

413 Maintate 103 99 102 Mitsubishi TanabePharma

Hypertension NA

413 Exforge 103 10 0 Novartis Hypertension Jan. 18, 2007(EU approval date)

415 Calblock 102 88 64 Daiichi Sankyo Hypertension 2003

415 Fosrenol 102 45 54 Shire PharmaceuticalsGroup

Phosphorus level reduction Oct. 26, 2004

415 Tykerb 102 0 0 GlaxoSmithKline Breast cancer March 13, 2007

418 Avandaryl 100 84 0 GlaxoSmithKline Type 2 diabetes Nov. 23, 2005

418 Levoxyl 100 112 140 King Pharmaceuticals Hypothyroidism May 25, 2001

418 Rinderon 100 101 102 Shionogi Ocular surface disorders NA

421 HANP 98 92 86 Daiichi Sankyo Acute heart failure NA

422 Sermion 95 102 114 Mitsubishi Tanabe

Pharma

Cerebral circulation June 1988

(Japan launch)422 Urief 95

Daiichi 54

Kissei 41

37

Daiichi 23Kissei 14

0 Daiichi Sankyo andKissei Pharmaceutical

Dysuria May 2006

422 Ethyol

Note: MedImmune2007 figure is afirst-half estimate;MedImmune wasacquired alongwith Ethyol byAstraZeneca inJune 2007.

95(estimate)

MedImmune 52(estimate)

AstraZeneca 43

87(MedImmune)

95(MedImmune)

AstraZeneca andMedImmune

Renal toxicity reduction Dec. 8, 1995

425 Flivas 94 93 91 Asahi Kasei Benign prostatichyperplasia

NA

425 Suvenyl 94 78 69 ChugaiPharmaceutical

Rheumatoid arthritis March 2000

425 Bezatol 94 98 106 Kissei Pharmaceutical Hyperlipidemia April 1991

428 Zoton 93 131 376 Wyeth Gastrointestinal disorders 1994

429 Colazal 92 103 110 Salix Pharmaceuticals Ulcerative colitis July 18, 2000

429 Plan B

Notes: 2007 includesRx and OTC salesas the two segmentswere not brokendown by Barr.

Barr changed froma June 30 fiscal yearfor 2006 and 2005 to

a Dec. 31 year endfor 2007.

92 NA NA Barr Pharmaceuticals Contraception July 28, 1999

431 Prexige 91 47 8 Novartis Osteoarthritic pain 2005 (Australia, Brazil,New Zealand,U.K. launches)

432 Venilon 89 94 93 Teijin Severe infectious diseases February 1980(Japan launch)

432 Noxafil 89 19 NA Schering-Plough Fungal infections Sept. 15, 2006(U.S. approval)

434 Zelnorm/Zelmac 88 561 417 Novartis Irritable bowel syndrome March 19, 2002/Oct. 30, 2001

434 TachoSil 88 84 64 Nycomed Tissue management NA

434 Glovenin 88 86 85 TakedaPharmaceutical

Blood disorders November 1991(Japan launch)


25/69

25


Rank2007 Medicine






434 Talion 88 70 64 Mitsubishi TanabePharma

Allergic rhinitis October 2000 (launch)

438 Aggrastat

Notes: Medicureacquired AggrastatU.S. rights from MGI

Aug. 8, 2006.

MGI acquired Aggra-stat U.S. rights fromGuilford Pharma-ceuticals in October2005.

87+

Merck 87

Medicure NA

90+

Merck 86

MGI 4

Medicure NA

99(estimate)

Merck 88

Guilford 9(estimate)MGI Pharma 2

Medicure 0

Merck & Co. andMedicure

Acute coronary syndrome May 1998 (U.S. launch)

438 Ultram ER 87+

Biovail 87

J&J NA

54+

Biovail 54

J&J NA

0 Biovail andJohnson & Johnson

Pain Feb. 21, 2006 (U.S. launch)

438 Meptin 87 37 NA OtsukaPharmaceutical

Bronchial musclerelaxation

1980 (Japan launch)

438 Farmorubicin andAdriacin

87 86 95 Kyowa Hakko Kogyo Cancers NA

442 Oxis 86 88 91 AstraZeneca Asthma March 4, 2001

442 Azactam 86 78 58 Elan Bacterial infections Dec. 31, 1986

442 Naglazyme 86 47 6 BioMarinPharmaceutical

Mucopolysaccharidosis May 31, 2005

442 Janumet 86 0 0 Merck & Co. Type 2 diabetes March 30, 2007(U.S. approval)

446 Pansporin 84 109 127 TakedaPharmaceutical

Bacterial infections February 1981(Japan launch)

446 Intal 84

Astellas 70

King 14

94

Astellas 79

King 15

96

Astellas 84

King 12

Astellas Pharma andKing Pharmaceuticals

Asthma May 29, 1986

448 Nolvadex 83 89 114 AstraZeneca Breast cancer Dec. 30, 1977

449 Tazorac, Zorac,Avage

80 91 87 Allergan Acne, facial wrinkles June 13, 1997,Dec. 12, 1996,

Sept. 30, 2002

449 Campral 80

Merck KGaA 49

Forest 31

79

Merck KGaA 49

Forest 30

70

Merck KGaA 47

Forest 23

Merck KGaA andForest Laboratories

Alcoholism U.S. approval:July 29, 2004U.S. launch:January 2005

451 Sonata 79 86 83 King Pharmaceuticals Insomnia Aug. 13, 1999

452 Dasen 77 81 85 TakedaPharmaceutical

Inflammation November 1968(Japan launch)

452 Rheumatrex 77 69 67 TakedaPharmaceutical

Rheumatoid arthritis August 1999(Japan launch)

452 Vyvanse 77 0 0 Shire PharmaceuticalsGroup

Attention deficithyperactivity disorder

July 27, 2007(U.S. launch)

455 Accolate 76 81 72 AstraZeneca Asthma Sept. 24, 1996

455 Mearubik 76 59 6 Mitsubishi TanabePharma

Measels and Rubellaimmunization

December 2005(launch)

457 Serostim

Note: Serono alongwith Serostim wereacquired by MerckKGaA Jan. 5, 2007.

75 72(Serono)

70(Serono)

Merck KGaA AIDS wasting Aug. 23, 1996

457 Atarax 75 74 67 UCB Anxiety NA

459 Dorner 74 78 85 Astellas Pharma Circulatory disorders 1992

459 Oxarol 74 65 62 ChugaiPharmaceutical

Hyperparathyroidism September 2000

459 Alkeran 74 50 50 Celgene Multiple myeloma,ovarian cancer

May 27, 1974


26/69


26

Rank2007 Medicine






459 Frova/Migard 74Endo 52 (Frova)

Menarini 22(Migard)

58

Endo 41 (Frova)

Menarini 17(Migard)

38+

Endo 38 (Frova)

Menarini NA(Migard)

EndoPharmaceuticalsHoldings andMenarini

Migraine Migard: January 2002(EU approval)

Frova: June 2002(U.S. launch)

459 Nisis and Nisisco 74 70 57 Ipsen Arterial hypertension NA

464 Estrace Cream 73 66 54 Warner Chilcott Menopausal symptoms Jan. 31, 1984(U.S. approval)

465 Carbatrol 72 68 72 Shire PharmaceuticalsGroup

Seizures Sept. 30, 1997

465 Efudex/Efudix 72 78 60 ValeantPharmaceuticals

Multiple actinic keratosesand superficial basal cellcarcinoma

Efudex: July 29, 1970(U.S. approval)

467 Neupro 71 14 0 UCB Parkinsons disease Feb. 20, 2006(Europe approval)

467 Forlax 71 63 59 Ipsen Constipation

469 Dogmatyl 70 73 78 Astellas Pharma Ulcers NA

469 Paragard

Note: Barr changedfrom a June 30 fiscal

year for 2006 and2005 to a Dec. 31year end for 2007.

70 NA NA Barr Pharmaceuticals Contraception Nov. 15, 1984

471 Xagrid 69 53 47 Shire PharmaceuticalsGroup

Thrombocythemia November 2004(EU approval)

472 Ranexa 67 18 0 CV Therapeutics Chronic angina March 24, 2006(U.S. launch)

473 OxyContin 66+

Purdue NA

Shionogi 66

52+

Purdue NA

Shionogi 52

43+

Purdue NA

Shionogi 43

Purdue Pharmaand Shionogi

Cancer pain Dec. 12, 1995(U.S. approval)July 7, 2003(Japan launch)

473 Perdipine andPerdipine LA

66 75 89 Astellas Pharma Hypertension 1981 and NA

473 Cefamezin 66 66 75 Astellas Pharma Bacterial infections NA

473 Symlin 66 44 12 AmylinPharmaceuticals

Diabetes March 16, 2005

473 Soliris 66 0 0 AlexionPharmaceuticals

Paroxysmal nocturnalhemoglobinuria

April 2007 (U.S. launch)

473 Atmadisc

Note: SchwarzPharma wasacquired by UCB inDecember 2006.

66 65(Schwarz)

61(Schwarz)

UCB Asthma Aug. 24, 2000

479 Ventavis

Notes: 2006 figureis an estimatebased onnine-month2006 sales ofCoTherix, which

was acquired byActelion in March2007.

Bayer acquiredSchering AG June23, 2006.

65+

Actelion 65

CoTherix NA

Bayer NA

65+(estimate)

CoTherix 65(estimate)

Bayer NA

24+

CoTherix 24

Schering NA

Actelion and Bayer Pulmonary arterialhypertension

Sept. 22, 2003(EU approval)

479 Canasa 65 53 29 Axcan Pharma Gastrointestinal disorders Jan. 5, 2001

481 Firstcin 64 69 75 TakedaPharmaceutical

Bacterial infections August 1995(Japan launch)

481 Xifaxan 64 52 30 Salix Pharmaceuticals Travelers diarrhea May 25, 2004

481 Cefspan 64 57 60 Astellas Pharma Bacterial infections NA

481 Daytrana 64 25 0 Shire PharmaceuticalsGroup

Attention deficithyperactivity disorder

June 29, 2006(U.S. launch)


27/69

27


Rank2007 Medicine






481 Femhrt 64 59 61 Warner Chilcott Menopausal symptoms Oct. 15, 1999(U.S. approval)

486 Targocid 63 64 70 Astellas Pharma Bacterial infections July 1998

486 Toledomin 63 60 62 Asahi Kasei Depression NA

486 Aptivus 63 73 NA Boehringer Ingelheim HIV infection June 22, 2005

489 Pentcillin 62 61 66 TaishoPharmaceutical

Bacterial infections NA

489 Bredinin 62 60 61 Asahi Kasei Kidney transplantation NA

489 Topotecin 62 54 48 Daiichi Sankyo Colorectal cancer NA

489 Omeprazon 62 59 70 Mitsubishi TanabePharma

Ulcers April 1991 (launch)

489 Novastan 62 54 38 Mitsubishi TanabePharma

Peripheral arterialocclusive disease

NA

494 Nauzelin 60 65 66 Kyowa Hakko Kogyo Gastrointestinal disorders NA

494 Sumiferon 60 64 60 Dainippon Sumitomo Hepatitis B and C 1987

494 Theo-Dur 60 77 127 Mitsubishi TanabePharma

Asthma April 1984 (launch)

497 Bicilin 59 43 54 King Pharmaceuticals Bacter ial infect ions May 19, 1957

497 Cabaser 59 99 103 Kissei Pharmaceutical Parkinsons disease September 1999

497 Antara 59 17 0 OscientPharmaceuticals

Hypercholesterolemia andhypertriglyceridemia

Nov. 30, 2004(U.S. approval)

500 Gastrom 58 61 64 Mitsubishi TanabePharma

Ulcers December 1993(launch)

500 Neuart 58 59 62 Mitsubishi TanabePharma

Disseminated intravascularcoagulation

June 1987 (launch)

NOTES/LEGEND:*First approval date or launch date = anywhere worldwide; in some instances, the first approval or launch date and region of occurrence are provided.*NA = not applicable.*+ = sales are assumed to be higher than the represented total.*This chart presents 500 medicines in sales order as reported by the companies. Certain products are represented by more than one company due to joint-marketing orjoint-promotion accords. The combined product sales from such company alliances are presented in this chart at the top of each medicine sales entry, followed by thebreakdown in company-reported sales.*Some product entries have their (chemical) listed depending on where and under which name the drug is marketed, or how the company reports the drugs sales.*All foreign product sales are reported in U.S. dollars using Federal Reserve or company-provided exchange rates.*Estimate = sales were not provided by company or found by Med Ad Newseditors, who made an estimate based on previous-year figures and/or other information

provided. This report does exclude certain products that probably would have been ranked in the top 500 list for 2007, but were omitted since no 2007 information couldbe found to make an estimate. In most of these instances, there are products with declining annual sales figures due to patent expirations.*All Japanese-company 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006), exceptfor Chugai Pharmaceutical and Kirin Brewery, which report annual sales on a Dec. 31 calendar-year basis.*Forest Laboratories 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006).*Barr Pharmaceuticals for 2007 reported on a Dec. 31 calendar-year basis; previously, the company provided figures for years ended June 30).*Axcan Pharma 2007 figures are for the fiscal year ended Sept. 30, 2007 (2006 = year ended Sept. 30, 2006; 2005 = year ended Sept. 30, 2005).


28/69

TOP 500PRESCRIPTION

MEDICINES

BY COMPANY


29/69

29

TOP 500 PRESCRIPTION MEDICINES BY COMPANY

Company Medicine2007 sales($ in millions)





Abbott Laboratories

Note: Abbott acquired KosPharmaceuticals (along withNiaspan and certain rights toCardizem and Teveten) Dec.13, 2006.

Humira 3,064 2,044 1,400 Rheumatoid arthritis Dec. 31, 2002

Depakote 1,575 1,308 1,096 Seizures March 10, 1983

Kaletra 1,325 1,135 1,005 HIV infection March 9, 2001

TriCor 1,218 1,048 927 Cholesterol Feb. 9, 1998

Ultane/Sevorane 759 799 874 Anesthesia June 7, 1995/1994

Biaxin 724 816 1,065 Bacterial infections Oct. 31, 1991

Niaspan 658 0 0 Cholesterol July 28, 1997

Synthroid 533 534 554 Hypothyroidism 1955

Omnicef 235 637 495 Bacterial infections Dec. 4, 1997

Lansoprazole 200 173 154 Gastrointestinal disorders NA

Cardizem LA 129(estimate)

NA 0 Hypertension Feb. 6, 2003

Teveten franchise 27(estimate)

NA 0 Hypertension Dec. 22, 1997(U.S. approval)

Leuprolide NA 230 219 Prostate cancer NA

Synagis

Note: Abbott completedthe U.S. joint-promotiondeal of Synagiswith MedImmune inDecember 2006)

0 373(U.S. jointpromotionrevenue)

231(U.S. jointpromotionrevenue)

Respiratory syncytial virus June 19, 1998(U.S. approval)

Mobic 0 0 1,232 Osteoarthritis andrheumatoid arthritis

Feb. 27, 1996

Abraxis Abraxane 325 175 134 Breast cancer February 2005(U.S. launch)

Diprivan

Note: Abraxis acquiredU.S. rights to Diprivanfrom AstraZeneca inJune 2006.

NA NA 0 Anesthesia Oct. 2, 1989

Actelion Tracleer 983 749 528 Pulmonary arterialhypertension

Nov. 20, 2001

Ventavis

Note: CoTherix and U.S.rights to Ventavis wereacquired by Actelion inMarch 2007.

65 0 0 Pulmonary arterial

hypertension

Sept. 22, 2003

(EU approval)

Akzo Nobel

Note: Akzo Nobel 2007product sales are estimatesfrom Jan. 1, 2007, thru Nov.18, 2007; Schering-Ploughacquired Akzo NobelsOrganon BioSciences as ofNov. 19, 2007.

Follistim/Puregon 513(estimate)

527 487 Infertility Sept. 29, 1997/May 3, 1996

NuvaRing 342(estimate)

292 174 Contraception June 12, 2001

Remeron 271(estimate)

347 388 Depression June 15, 2000

Livial 177(estimate)

207 211 Menopausal symptoms March 1997

Alexion Pharmaceuticals Soliris 66 0 0 Paroxysmal nocturnalhemoglobinuria

April 2007 (U.S. launch)

Allergan Botox 1,212 982 831 Cervical dystonia Dec. 29, 1989

Lumigan franchise 392 328 268 Intraocular pressure March 16, 2001

Restasis 345 270 191 Dry eye Dec. 23, 2002

Alphagan P, Alphagan,Combigan

341 296 277 Intraocular pressure March 16, 2001, Sept. 6,1996, fourth-quarter 2003

Tazorac, Zorac, Avage 80 91 87 Acne, facial wrinkles June 13, 1997, Dec. 12,1996, Sept. 30, 2002

Alpharma Kadian 168 138 102 Pain July 3, 1996

Altana Pharma

Note: Nycomed acquiredAltana Pharma along withPantoprazole productsDec. 29, 2006.

Pantoprazole(including Pantozol)

0 2,126 1,866 Gastrointestinal disorders Pantozol: 1994


30/69

30

TOP 500 PRESCRIPTION MEDICINES BY COMPANY

Company Medicine2007 sales($ in millions)





Amgen Aranesp 3,614 4,121 3,273 Anemia June 11, 2001

Enbrel 3,230 2,879 2,573 Rheumatoid arthritis Nov. 2, 1998

Neulasta 3,000 2,710 2,288 Neutropenia Jan. 31, 2002

Epogen 2,489 2,511 2,455 Anemia June 1, 1989

Neupogen 1,277 1,213 1,216 Neutropenia Feb. 20, 1991

Sensipar 463 321 157 Hypercalcemia March 8, 2004

Vectibix 170 39 0 Colorectal cancer Sept. 27, 2006

Amylin Pharmaceuticals Byetta 636 430 75 Type 2 diabetes April 28, 2005

Symlin 66 44 12 Diabetes March 16, 2005

Asahi Kasei Elcitonin 139 138 152 Osteoporosis NA

Flivas 94 93 91 Benign prostatic hyperplasia NA

Toledomin 63 60 62 Depression NA

Bredinin 62 60 61 Kidney transplantation NA

Astellas

Documents

Top 500 Medicines Pharma